peramivir and Shock--Cardiogenic

The outbreak and spread of the new influenza A subtype H1N1 reached pandemic levels during 2009, with greater numbers of cases reported daily and numerous complications described. The present report concerns an atypical manifestation of the disease in a previously healthy middle-aged patient who presented with severe, refractory cardiogenic shock 4 days after being diagnosed as having influenza A. The patient was considered for emergency heart transplant. Successful treatment involved the use of a left ventricular assist device, extracorporeal membrane oxygenation, intravenous immunoglobulin and peramivir as therapeutics and bridging therapies for transplant. This case is a report of H1N1 fulminant myocarditis and illustrates the usefulness of a multidisciplinary approach in the care of these patients.

Topics: Acids, Carbocyclic; Antiviral Agents; Combined Modality Therapy; Cyclopentanes; Extracorporeal Membrane Oxygenation; Female; Guanidines; Humans; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Myocarditis; Shock, Cardiogenic